Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
Ibandronate was granted FDA approval on 16 May 2003.
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT01290094
Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids
- Conditions
- OsteopeniaOsteoporosisRheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Yeong-Wook Song
- Target Recruit Count
- 167
- Registration Number
- NCT01287533
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6054
- Registration Number
- NCT01128257
Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
- Conditions
- AdenocarcinomaEsophageal CancerSquamous Cell Carcinoma
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 684815
- Registration Number
- NCT01077817
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 833
- Registration Number
- NCT00936897
S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307
- Conditions
- Breast Cancer
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00873808
- Locations
- 🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
- Conditions
- Hematological Malignancies
- Interventions
- Drug: Vitamin Supplements
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT00824993
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
PTH & Ibandronate Combination Study (PICS)
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 44
- Registration Number
- NCT00683163
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
- Conditions
- Post-menopausal Osteoporosis
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2018-03-06
- Target Recruit Count
- 410
- Registration Number
- NCT00666627
- Locations
- 🇬🇧
Academic Unit of Bone Metabolism (Sheffield), Sheffield, South Yorkshire, United Kingdom
Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort
- Conditions
- HIV Infections
- Interventions
- Behavioral: Lifestyle modifications
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Registration Number
- NCT00662077
- Locations
- 🇪🇸
Germans Trias i Pujol Hospital - Lluita Sida Foundation, Badalona, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.